GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1beta with IC50s of 0.4 µM (human IL-1beta) and 0.1 µM (mouse IL-1beta). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation[1][2].